Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 11, 2024 21:27 ET
|
Belite Bio, Inc
Tinlarebant is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related...
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
March 06, 2024 08:00 ET
|
Belite Bio, Inc
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
March 04, 2024 08:00 ET
|
Belite Bio, Inc
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024 08:00 ET
|
Belite Bio, Inc
SAN DIEGO, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
November 30, 2023 08:00 ET
|
Belite Bio, Inc
SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite Bio to Participate in the BTIG Ophthalmology Day
November 20, 2023 08:00 ET
|
Belite Bio, Inc
SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
November 13, 2023 20:15 ET
|
Belite Bio, Inc
Completed enrollment in pivotal Phase 3 “DRAGON” trial for Tinlarebant in adolescent Stargardt disease (“STGD1”) with 104 subjects enrolled across 11 countries worldwideFirst subject dosed with...
Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results
November 07, 2023 08:00 ET
|
Belite Bio, Inc
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting...
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting
November 06, 2023 08:00 ET
|
Belite Bio, Inc
Tinlarebant (a/k/a LBS-008) is Belite Bio’s orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced...
Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting
October 27, 2023 08:00 ET
|
Belite Bio, Inc
Two-year data from the two-year Phase 1b/2 trial of Tinlarebant (LBS-008) in adolescent Stargardt Disease (STGD1) to be presentedA two-year global Phase 3 trial in adolescent STGD1 (the “DRAGON”...